

- ❖ **Name & Designation** : Dr. Kartik H. Doshi, Senior Resident
- ❖ **Address** : Dept. of Clinical Pharmacology, ACTREC, Kharghar, Navi Mumbai-410210
- ❖ **Name of the International Conference/ Seminar/Symposium/ Workshop** : Milan, Italy, 30th March to 2nd April 2014
- ❖ **Title of the abstract accepted** : Utility of posaconazole monitoring and factors affecting its levels in patients undergoing hematopoietic stem cell transplantation: Single center experience from India
- ❖ **Venue & Date** : Milan, Italy, 30th March to 2nd April 2014.
- ❖ **Money sanctioned** : ₹ 1,00,000/-
- ❖ **Money reimbursed** : ₹ 38,177/-

Participation Report

This year the 40th Annual Meeting of the European Society for Blood and Marrow Transplantation -2014, was held at Milan (Italy). The conference was attended by physicians, scientists, nurses and data managers associated with bone marrow transplantation. Around 4600 participants from all over the world attended the conference. The scientific programme included symposia, educational sessions and workshops covering the key issues relating to blood and marrow transplantation.

Academic highlights

There were 8 plenary sessions, 25 scientific sessions, 13 CMEs and 10 pharma sponsored sessions held simultaneously. The conference was a platform for participants from all over the world, to pursue new research and breakthrough advancements in cell therapy, immunotherapy and stem cell transplantation. It essentially highlighted the optimum use of antifungal therapy, T

cell therapy and new advances in bone marrow transplantation and encouraged spontaneous participation by delegates.

New developments discussed in conference.

1. T cell based chimeric receptor antigen (CAR) targeting CD 19 causes less GVHD in children and adults with relapsed/refractory ALL.
2. Cooperative trials and feasibility of BMT in solid tumors.
3. Newer drugs and regime for different indications in BMT.

New developments resulting from the training/Workshops –

T cell based therapy was the main highlight of this conference. Research on T cell based therapy has successfully shown that chimeric receptor antigen (CAR) can be successfully utilized for less no. of graft versus host disease (GVHD) episodes. Gene therapy has also been utilized in GVHD therapy.

There are some encouraging results for doing bone marrow transplantation in solid tumors. The conference also introduced us to the use of newer drugs and their cost-benefit analysis in patients.

Participant contribution in conference

At the 40th EBMT conference held in Milan (Italy) between 30th March- 2nd April, 2014 was a grand gathering of BMT physicians, scientists, nurses and data managers related to Bone marrow transplantation. We, as a team of BMT physicians and scientists from the premier institute ACTREC, TMH, represented India adequately with our poster presentations.

The primary purpose of our visit was to exchange thoughts and research ideas put forward by our institute for the betterment of patients and their families.

My **topic of presentation** at the conference is mentioned below.

“Utility of posaconazole monitoring and factors affecting its levels in patients undergoing hematopoietic stem cell transplantation: single center experience from India.”